Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553391 | 0.91 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DMMP2 | |
| SCHEMBL8569941 | 0.90 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DMMP2 | |
| Hydrochloric Acid SCHEMBL8571356 | 0.89 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DMMP2 | |
| SCHEMBL1553474 | 0.89 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DRNASEH1 | |
| SCHEMBL8571347 | 0.88 | PDE4D (0.59) | PDE4APDE4BPDE4CPDE4DMMP2 | |
| SCHEMBL1553615 | 0.85 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL8570416 | 0.84 | PDE4D (0.52) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1554630 | 0.83 | GAA (0.46) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL8574236 | 0.82 | MTNR1A (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8570317 | 0.82 | PDE4D (0.52) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120288482-A1 | THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-11-15 | — | — | US | disclosed |
| EP-1459743-B9 | Agent for prophylaxis and treatment of glaucoma | SENJU PHARMA CO (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-1459742-B9 | Agent for prophylaxis and treatment of asthenopia and pseudomyopia | SENJU PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1459743-B1 | Agent for prophylaxis and treatment of glaucoma | SENJU PHARMA CO (JP) | 2011-10-19 | — | — | EP | disclosed |
| EP-1459742-B1 | Agent for prophylaxis and treatment of asthenopia and pseudomyopia | SENJU PHARMA CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-1295607-B9 | ANTITUMOR EFFECT POTENTIATORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-7956072-B2 | Agent for repairing corneal sensitivity containing amide compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| EP-0934307-B1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2011-04-27 | — | — | EP | disclosed |
| EP-1177796-B1 | Medicament for prevention or therapeutic treatment of liver disease | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2223920-A2 | Substituted azabicyclic compounds | Aventis Pharma Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-6156766-A | Benzamide compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-1034793-A1 | PREVENTIVES/REMEDIES FOR GLAUCOMA | Senju Pharmaceutical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0641781-B1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
| US-5478838-A | Treating hypertension, angina pectoris, asthma, improving peripheral circulation | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0641781-A1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288482-A1 | THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION | YES1, VCAM1, EDF1 | PDE4A 1007/4885PDE4B 1733/4885PDE4C 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.